Abstract
Objective
Resistant hypertension is an important clinical problem that is poorly studied and not well managed. The objective of this study was to identify factors associated with successful treatment of resistant hypertension in a specialty clinic.
Methods
This was a retrospective observational study examining the medical records of patients seen at a specialty hypertension clinic at the University of Rochester, Rochester, New York, USA, in the year 2005. The records of 68 patients were reviewed. Those presenting with resistant hypertension (defined as BP ≥140/ 90mm Hg and receiving at least three antihypertensive medications, including a diuretic) were identified. Change in medication type and dosage, BP reduction, and percentage of patients at Joint National Committee (JNC)-7 goal were noted.
Results
Twenty-eight patients were included in the analysis. Mean age was 62.5 ± 11.6 years, 54% were women, and mean presenting BP was 175.4 ± 23.5/87.5 ± 14.6mm Hg. After an average of 6.2 ± 3.2 visits over a mean of 13.9 ± 13.5 months, mean BP was reduced to 145.3 ± 27.7/73.9 ± 13.6mm Hg (paired t-test: p = 0.001 SBP, p = 0.0001 DBP), and 44.8% of the patients were at their JNC-7 goal. Change in the mean number of antihypertensive medications was not significantly different between the initial and final clinic visits (4.1 ± 1.2 vs 4.2 ± 1.0; p = 0.627). Combination pill use increased from four patients (14%) at initial visit to 19 (68%) at final visit. Numbers of patients treated with diuretics, β-adrenoceptor antagonists, calcium channel antagonists (CCB), and minoxidil increased at the final clinic visit. Significant dose-related changes included the up-titration of CCBs to high doses, and the initiation of moderate doses of thiazide diuretics; mainly chlorthalidone (67% final visit vs 0% at initial visit).
Conclusions
Patients referred to a specialty clinic for the control of resistant hypertension achieved significant reductions in BP with frequent visits, combination pills, and greater use and higher doses of CCBs and thiazide diuretics.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alderman MH, Budner N, Cohen H, et al. Prevalence of drug resistant hypertension. Hypertension 1988; 11 Suppl. II: II71–5.
Swales JD, Bing RF, Heagerty AM, et al. Treatment of refractory hypertension. Lancet 1982; 1: 894–6.
McAlister FA, Lewanczuk RZ, Teo KK. Resistant hypertension: an overview. Can J Cardiol 1996; 12: 822–8.
Lapuerta P, Simon T, Smitten A, et al., on behalf of the CHOICE Study Group. Caring for hypertension on initiation: costs and effectiveness. Clin Ther 2001; 23: 1773–82.
Paramore LC, Halpern MT, Lapuerta P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care 2001; 7: 389–98.
Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med 1991; 151: 1786–92.
Ferrari P, Hess L, Pechere-Bertschi A, et al. Reasons for not intensifying anithypertensive treatment (RIAT): a primary care antihypertesive intervention study. J Hypertens 2004; 22: 1221–9.
Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Inernt Med 2002; 162: 413–20.
Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep 2002; 4: 221–8.
Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002; 40: 464–9.
Wong ND, Thakral G, Franklin SS, et al. Preventing heart disease by controlling hypertension: impact of hypertensive subtype, stage, age, and sex. Am Heart J 2003; 145: 888–95.
Steinman MA, Fischer MA, Shlipak MG, et al. Clinical awareness of adherence to hypertension guidelines. Am J Med 2004; 117: 747–54.
Garg JP, Elliot WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university based-cohorts. Am J Hypertens 2005; 18: 619–26.
Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 42: 4–9.
Enst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47: 352–8.
Khosla N, Chua DY, Elliot WJ, et al. Are chlorthalidone and hydrochlorothiazide equivalent blood pressure-lowering medications? J Clin Hypertens 2005; 7: 354–6.
The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. JAMA 2002; 18: 2981–97.
Nishizaka MK, Calhoun DA. Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens 2004; 6: 458–60.
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–31.
Acknowledgments
The authors have no financial interests or disclosures relevant to the content of this study. Dr Bisognano had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fong, M.W., Filippone, J.D., Beck, G.R. et al. Improving Care in Resistant Hypertension. Am J Cardiovasc Drugs 7, 449–452 (2007). https://doi.org/10.2165/00129784-200707060-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00129784-200707060-00008